# Viatris

Source: https://onco.cc/companies/viatris/  
OnCo record `viatris` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Viatris is the generics and biosimilars group formed in 2020 from Mylan and Pfizer's Upjohn; in cancer care it supplies generic chemotherapies and biosimilar trastuzumab and pegfilgrastim, and Mylan's phase 3 biosimilar trials sit under its name.

## Summary

Viatris was created in November 2020 by the merger of Mylan with Upjohn, Pfizer's off-patent medicines business, and is headquartered in Pittsburgh. Its oncology footprint is generic injectable chemotherapies and biosimilars developed with Biocon, including trastuzumab (Ogivri) and pegfilgrastim (Fulphila), whose comparative phase 3 trials were run by Mylan. ClinicalTrials.gov lists Mylan as lead sponsor of those trials, which OnCo attributes to Viatris.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Mylan; Mylan Inc.; Mylan Pharmaceuticals Inc.; Mylan N.V.; Upjohn
- Tags: ctgov-sponsor
- HQ: Pittsburgh, PA
- Type: pharma
- Website: https://www.viatris.com

## Sources

- Official website: https://www.viatris.com
- ClinicalTrials.gov: trials led by Mylan: https://clinicaltrials.gov/search?lead=Mylan
- Wikidata: https://www.wikidata.org/wiki/Q101983981

## Connected records

- technologies: [Growth factors: G-CSF and febrile neutropenia prevention](https://onco.cc/technologies/g-csf-growth-factors/)
- drugs: [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/), [Trastuzumab biosimilars](https://onco.cc/drugs/trastuzumab-biosimilars/)
- companies: [Biocon Biologics](https://onco.cc/companies/biocon-biologics/)
- terms: [Biosimilar](https://onco.cc/terms/biosimilar/), [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/viatris.json